new glp 1 drug retatrutide for weight loss: Study shows 30% body weight loss Next-Gen GLP-1 after Ozempic: Retatrutide
Description
Such differences must be medically necessary and documented for individual patients
10.1136/bmjopen-2022-061807 40
It is currently in Phase 3 trials, and FDA approval is not expected until late 2026
However, as their popularity has increased so have reports of side effects associated with these agents
